Dybowska Małgorzata, Błasińska Katarzyna, Gątarek Juliusz, Klatt Magdalena, Augustynowicz-Kopeć Ewa, Tomkowski Witold, Szturmowicz Monika
Department of Lung Diseases, National Tuberculosis and Lung Diseases Research Institute, 01-138 Warsaw, Poland.
Department of Radiology, National Tuberculosis and Lung Diseases Research Institute, 01-138 Warsaw, Poland.
Diagnostics (Basel). 2022 Mar 2;12(3):619. doi: 10.3390/diagnostics12030619.
Tuberculous pericarditis (TBP) accounts for 1% of all forms of tuberculosis and for 1-2% of extrapulmonary tuberculosis. In endemic regions, TBP accounts for 50-90% of effusive pericarditis; in non-endemic, it only accounts for 4%. In the absence of prompt and effective treatment, TBP can lead to very serious sequelae, such as cardiac tamponade, constrictive pericarditis, and death. Early diagnosis of TBP is a cornerstone of effective treatment. The present article summarises the authors' own experiences and highlights the current status of knowledge concerning the diagnostic and therapeutic algorithm of TBP. Special attention is drawn to new, emerging molecular methods used for confirmation of infection as a cause of pericarditis.
结核性心包炎(TBP)占所有结核病形式的1%,占肺外结核病的1%-2%。在结核病流行地区,TBP占渗出性心包炎的50%-90%;在非流行地区,仅占4%。若不及时进行有效治疗,TBP可导致非常严重的后遗症,如心脏压塞、缩窄性心包炎和死亡。TBP的早期诊断是有效治疗的基石。本文总结了作者自身的经验,并着重介绍了关于TBP诊断和治疗流程的当前知识状况。特别关注用于确诊感染是心包炎病因的新兴分子方法。